Takeda Pharmaceutical Co. (TAK)
(Delayed Data from NYSE)
$15.02 USD
-0.07 (-0.46%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $15.04 +0.02 (0.13%) 7:58 PM ET
5-Strong Sell of 5 5
B Value C Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Takeda Pharmaceutical Co. has a PEG ratio of 0.26 compared to the Medical - Drugs industry's PEG ratio of 1.42.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TAK 15.02 -0.07(-0.46%)
Will TAK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TAK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TAK
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
Will Strong Asceniv Sales Drive ADMA Biologics Further?
TAK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?
Other News for TAK
Is TAK positioned for a breakdown? 20 Day Moving Average Resistance shows up after declining 0.2%
Novavax: Endlessly Frustrating, Endlessly Fascinating - Warrants Rating Upgrade
TAK forms NR7 on September 16
Takeda Flat on Hookup with VELA
Takeda, Vela Transport announce medicine shipping partnership